BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33788757)

  • 1. Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
    Sato Y; Iihara H; Kinomura M; Hirose C; Fujii H; Endo J; Yanase K; Kaito D; Sasaki Y; Gomyo T; Sakai C; Iwai M; Tsuboi Y; Ishihara T; Kobayashi R; Ohno Y; Suzuki A
    Anticancer Res; 2021 Mar; 41(3):1615-1620. PubMed ID: 33788757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
    Sekikawa M; Murakami H; Morita M; Doshita K; Miura K; Kodama H; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Chiba H; Takahashi T
    Thorac Cancer; 2023 Dec; 14(35):3475-3482. PubMed ID: 37873674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 5. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Spigel DR; Hainsworth JD; Shipley DL; Mekhail TM; Zubkus JD; Waterhouse DM; Daniel DB; Burris HA; Greco FA
    Lung Cancer; 2018 Mar; 117():38-43. PubMed ID: 29496254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
    Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
    Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
    Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
    Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
    Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.
    Wang X; Ren J; Liang X; He P
    Hematology; 2021 Dec; 26(1):950-955. PubMed ID: 34904529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
    Baig H; Somlo B; Eisen M; Stryker S; Bensink M; Morrow PK
    J Oncol Pharm Pract; 2019 Oct; 25(7):1576-1585. PubMed ID: 30200842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
    Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
    Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
    Mouri A; Kaira K; Shiono A; Yamaguchi O; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):1005-1008. PubMed ID: 30859745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis.
    Zhu X; Zhang W; Zhang Y; Wang Y; Hu H; Li J; Zhou Y; Han T; Huang D
    Hematology; 2023 Dec; 28(1):2172292. PubMed ID: 36719297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
    Ohkura Y; Ueno M; Udagawa H
    World J Surg Oncol; 2019 Jul; 17(1):125. PubMed ID: 31315622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
    Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
    Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.